Elcelyx Forms Its Own Fund To Lead $20 Million Series C Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
The money raised will bring the San Diego company’s total to $43 million and will be used to advance its delayed-release metformin, NewMet, through Phase IIb and into a partnership. The cash also will fund an efficacy trial for over-the-counter dietary supplement Lovidia.